Oncomed Pharmaceuticals (NASDAQ: OMED) is one of 186 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it contrast to its competitors? We will compare Oncomed Pharmaceuticals to related businesses based on the strength of its risk, dividends, earnings, profitability, analyst recommendations, valuation and institutional ownership.

Insider & Institutional Ownership

39.4% of Oncomed Pharmaceuticals shares are held by institutional investors. Comparatively, 49.8% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 32.8% of Oncomed Pharmaceuticals shares are held by insiders. Comparatively, 14.7% of shares of all “Biotechnology & Medical Research” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Volatility & Risk

Oncomed Pharmaceuticals has a beta of 2.8, suggesting that its share price is 180% more volatile than the S&P 500. Comparatively, Oncomed Pharmaceuticals’ competitors have a beta of 1.55, suggesting that their average share price is 55% more volatile than the S&P 500.

Profitability

This table compares Oncomed Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Oncomed Pharmaceuticals -298.57% N/A -48.03%
Oncomed Pharmaceuticals Competitors -3,347.21% -538.39% -40.53%

Valuation & Earnings

This table compares Oncomed Pharmaceuticals and its competitors top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Oncomed Pharmaceuticals $25.15 million -$103.10 million -2.45
Oncomed Pharmaceuticals Competitors $217.29 million -$39.39 million -100.35

Oncomed Pharmaceuticals’ competitors have higher revenue and earnings than Oncomed Pharmaceuticals. Oncomed Pharmaceuticals is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a breakdown of current ratings for Oncomed Pharmaceuticals and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oncomed Pharmaceuticals 0 6 2 0 2.25
Oncomed Pharmaceuticals Competitors 528 2359 6530 123 2.65

Oncomed Pharmaceuticals presently has a consensus target price of $6.00, suggesting a potential upside of 29.59%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 25.96%. Given Oncomed Pharmaceuticals’ higher possible upside, analysts clearly believe Oncomed Pharmaceuticals is more favorable than its competitors.

Summary

Oncomed Pharmaceuticals competitors beat Oncomed Pharmaceuticals on 7 of the 12 factors compared.

Oncomed Pharmaceuticals Company Profile

OncoMed Pharmaceuticals, Inc. (OncoMed) is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing therapeutics that address the fundamental biology driving cancer’s growth, resistance, recurrence and metastasis. The Company’s therapeutic candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Navicixizumab (Anti-DLL4/VEGF Bispecific, OMP-305B83), Anti-RSPO3 (OMP-131R10), Anti-TIGIT (OMP-313M32) and GITRL-Fc trimer (OMP-336B11). Demcizumab is a humanized monoclonal antibody that inhibits Delta-like Ligand 4 (DLL4) in the Notch signaling pathway. Tarextumab is a human monoclonal antibody that binds to both the Notch2 and Notch3 receptors.

Receive News & Ratings for Oncomed Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncomed Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.